Why Is SEPTERNA INC (SEPN) Stock Up Today?

SEPN stock is up 21.13% to $47.06 in a volatile session driven by a series of analyst upgrades and positive financial results. Multiple analysts raised price targets for Septerna, citing progress in its drug pipeline and the Q2 2026 earnings report, which showed better-than-expected revenue and earnings. The stock opened with a small gap up and surged to a session high of $47.31 before settling near that level.

What Happened

The Fly and Investing.com reported that Raymond James and Guggenheim raised their price targets for SEPN to $49 and $51 respectively, citing progress in the company’s pipeline and the SEP-479 program. Stifel also raised its price target to $49. These upgrades came alongside Septerna’s Q2 2026 earnings report, which showed a GAAP EPS of -$0.29, beating expectations by $0.16, and revenue of $26.75 million, exceeding estimates by $7.53 million. The SEC 8-K filing confirmed the financial results and highlighted $516.5 million in cash and equivalents, with the company projecting that it is funded through at least 2029.

What The Data Shows

The stock opened at $39.57, a modest 1.9% gap up from the prior close, but surged to a high of $47.31 during the session. Volume has reached 0.5 million shares, 1.2 times the 3-month average. Septerna’s fundamentals remain unprofitable, with a TTM net margin of -49.9% and a TTM EPS of -0.81, but revenue has grown by 7,295.6% TTM. The stock is currently trading near its 52-week high of $40.65, and the market cap is $1.8 billion.

What To Watch

Septerna has no upcoming earnings date, but investors will monitor coverage breadth as the stock moves beyond its 52-week high. Analyst upgrades and further pipeline developments could shape the next phase of the stock’s trajectory.